RICHLAND, WASHINGTON – March 31, 2021 – A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further...
Newsroom
Isoray, Inc. Announces Proposed Underwritten Public Offering
RICHLAND, Wash., October 19, 2020 -- Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it intends to offer and...
Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2020 Financial Results
Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year RICHLAND, WASHINGTON – September 17, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment...

Isoray to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
RICHLAND, WASHINGTON – September 16, 2020 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori...
Isoray To Announce Fourth Quarter and Fiscal Year End 2020 Financial Results on September 17, 2020
Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 10, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a...
Isoray and University of Cincinnati Physicians Company Sign Research Agreement to Study Treatment of Head and Neck Cancers
Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgical Resection RICHLAND, Wash., June 17, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that it has entered into a research grant agreement with the...
Second Ten Year Data Report Demonstrates Efficacy of Isoray’s Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer
RICHLAND, WASHINGTON – June 2, 2020 – Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 (Cesium Blu) internal...
Centers for Medicare and Medicaid Services Approves Isoray’s Application for Billing Codes for the Intraoperative Use of Cesium-131
RICHLAND, WASHINGTON – May 12, 2020 – Isoray, Inc. (NYSE American: ISR) today announced that the Centers for Medicare and Medicaid Services (CMS) has approved 64 ICD-10-PCS billing codes used for reimbursement of Cesium-131 (Cesium Blu™) for the hospital in-patient...
Isoray Announces Record Third Quarter Fiscal 2020 Financial Results
Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year RICHLAND, WASHINGTON – May 12, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body,...
Isoray To Announce Third Quarter Fiscal 2020 Financial Results on May 12, 2020
Conference Call is May 12 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – May 4, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced that it...
Isoray Announces Second Quarter Fiscal 2020 Financial Results
Revenue Increased 16% Year-Over-Year Gross Profit Increased 45% Year-Over-Year RICHLAND, WASHINGTON – February 11, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...
Isoray Collaborates with MIM Software to Deliver an Advanced Treatment Solution for Recurrent Head and Neck Cancers
Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients Facing Limited Options RICHLAND, WASHINGTON – February 5, 2020 – Isoray, Inc. (NYSE American: ISR) today announced an executed agreement with MIM Software to deliver a novel...
Isoray To Announce Second Quarter Fiscal 2020 Financial Results on February 11, 2020
Conference Call is Tuesday, February 11, 2020 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – January 31, 2020– Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...